December 01, 2017

CFIUS completes review of proposed merger of Bayer and Monsanto

Leverkusen/St. Louis, December 1, 2017 - Bayer and Monsanto (NYSE: MON) today
announced that the Committee on Foreign Investment in the United States
("CFIUS") has completed its review of the proposed merger, and has concluded
that there are no unresolved national security concerns with respect to the

The acquisition is subject to customary closing conditions, including receipt
of required regulatory approvals. Bayer and Monsanto will continue to cooperate
with the authorities in order to complete the transaction in early 2018.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2016, the Group
employed around 99,600 people and had sales of EUR 34.9 billion. Capital
expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For
more information, go to

About Monsanto Company

Monsanto is committed to bringing a broad range of solutions to help nourish
our growing world. We produce seeds for fruits, vegetables and key crops - such
as corn, soybeans, and cotton - that help farmers have better harvests while
using water and other important resources more efficiently. We work to find
sustainable solutions for soil health, help farmers use data to improve farming
practices and conserve natural resources, and provide crop protection products
to minimize damage from pests and disease. Through programs and partnerships,
we collaborate with farmers, researchers, nonprofit organizations, universities
and others to help tackle some of the world's biggest challenges. To learn more
about Monsanto, our commitments and our more than 20,000 dedicated employees,
please visit Follow our business on Twitter® at

Further information about the proposed transaction is available on the internet

Cautionary Statements Regarding Forward-Looking Information
Certain statements contained in this communication may constitute "forward-
looking statements." Actual results could differ materially from those
projected or forecast in the Forward-looking statements
. The factors that could
cause actual results to differ materially include the following: uncertainties
as to the timing of the transaction; the possibility that the parties may be
unable to achieve expected synergies and operating efficiencies in the merger
within the expected time-frames or at all and to successfully integrate
Monsanto's operations into those of Bayer; such integration may be more
difficult, time-consuming or costly than expected; revenues following the
transaction may be lower than expected; operating costs, customer loss and
business disruption (including, without limitation, difficulties in maintaining
relationships with employees, customers, clients or suppliers) may be greater
than expected following the announcement of the transaction; the retention of
certain key employees at Monsanto; risks associated with the disruption of
management's attention from ongoing business operations due to the transaction;
the conditions to the completion of the transaction may not be satisfied, or
the regulatory approvals required for the transaction may not be obtained on
the terms expected or on the anticipated schedule; the parties' ability to meet
expectations regarding the timing, completion and accounting and tax treatments
of the merger; the impact of the refinancing of the loans taken out for the
transaction, the impact of indebtedness incurred by Bayer in connection with
the transaction and the potential impact on the rating of indebtedness of
Bayer; the effects of the business combination of Bayer and Monsanto, including
the combined company's future financial condition, operating results, strategy
and plans; other factors detailed in Monsanto's Annual Report on Form 10-K
filed with the SEC for the fiscal year ended August 31, 2017 and Monsanto's
other filings with the SEC, which are available at and on
Monsanto's website at; and other factors discussed in Bayer's
public reports which are available on the Bayer website at Bayer
and Monsanto assume no obligation to update the information in this
communication, except as otherwise required by law. Readers are cautioned not
to place undue reliance on these forward-looking statements that speak only as
of the date.